ArticleNature communications2026
Engineering human PEG10-based nanoparticles for RNA self-packaging, delivery and cancer therapy.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PEG10 protein was recently uncovered to self-assemble and self-package its own mRNA into nanoparticles, but the particles require expensive transfection for production and have yet to be explored for cancer therapy. Here we develop a human PEG10-based nanoparticles (PBNPs) platform for cargo RNA self-packaging and delivery for cancer therapy. We design a process to improve the PBNPs production for 11.3-fold while reducing the cost. The PBNPs self-package mRNA of at least 7336 nucleotides and remain stable for 7 months. We engineer the PBNPs surface and tremendously improve mRNA delivery efficiencies to various cancer cells, particularly colon cancer cells (≈71%). We further reprogram the PBNPs to deliver an immunotherapeutic mRNA cocktail to colon cancer cells, which elicits T cell responses in vitro. In vivo co-administration of the engineered PBNPs and chemodrug in female mice synergizes immune responses and promotes anti-cancer efficacy, implicating the potential of PBNPs as an RNA delivery vehicle for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.